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Twice-weekly carfilzomib is approved at 27 and 56 mg/m
2 to treat
relapsed multiple myeloma patients. In the phase III study ARROW,
once-weekly 70 mg/m2 carfilzomib prolonged the median progres-
sion-free survival of relapsed multiple myeloma patients in comparison with
twice-weekly 27 mg/m2 carfilzomib, without adding significant toxicity.
Data were pooled from two phase I/II studies of newly diagnosed multiple
myeloma patients who received nine induction cycles of carfilzomib (either
70 mg/m2 once-weekly or 36 mg/m2 twice-weekly), cyclophosphamide and
dexamethasone, followed by carfilzomib maintenance. Overall, 121 trans-
plant-ineligible patients with newly diagnosed multiple myeloma were ana-
lyzed (once-weekly, n=63; twice-weekly, n=58). We found no significant dif-
ference in median progression-free survival [35.7 months (95%CI: 23.7-not
reached, NR) vs. 35.5 months (95%CI: 24.3-NR); HR: 1.39; P=0.26] and 
3-year overall survival [70% [95%CI:  59%-84%) vs. 72% (95%CI:  60%-
85%); HR: 1.27; P=0.5] between once-weekly and twice-weekly carfilzomib.
From the start of maintenance, 3-year progression-free survival [47%
(95%CI:  33%-68%) vs. 51% (95%CI: 38%-70%); HR: 1.04; P=0.92] and
overall survival [72% (95%CI: 58%-89%) vs. 73% (95%CI: 59%-90%); HR:
0.82; P=0.71] were similar in the once- versus twice-weekly carfilzomib. The
rate of grade 3-5 hematologic (24% vs. 30%; P=0.82) and non-hematologic
(38% vs. 41%; P=0.83) adverse events was similar in the two groups. Once-
weekly 70 mg/m2 carfilzomib as induction and maintenance therapy for
newly diagnosed multiple myeloma patients was as safe and effective as
twice-weekly 36 mg/m2 carfilzomib and provided a more convenient sched-
ule. The trials are registered at clinicaltrials.gov identifiers: 01857115 (IST-CAR-
561) and 01346787 (IST-CAR-506).
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ABSTRACT
Introduction
In the last two decades, several novel agents of various
classes have been developed and approved to treat multi-
ple myeloma (MM), resulting in improved overall survival
(OS) for both transplant-eligible and -ineligible patients.1
Among new agents, the immunomodulatory drugs (IMiD)
thalidomide and lenalidomide, and the proteasome
inhibitor (PI) bortezomib, have been included in the initial
treatment for newly diagnosed (ND) MM patients.
Bortezomib, a first-generation PI, proved to be a very effec-
tive anti-MM agent. It was initially approved for the
relapse setting and then approved for upfront therapy.
Despite the efficacy of bortezomib, its long-term adminis-
tration is limited by the emergence of peripheral neuropa-
thy, which was reported in 4-13% of patients (grade 3-4).2,3
Carfilzomib, a second-generation PI, showed significant
activity among patients with relapsed and/or refractory
(RR) MM and was approved by US Food and Drug
Administration and the European Medicines Agency in
combination with dexamethasone or lenalidomide-dex-
amethasone (Rd) for the treatment of RRMM patients.
Given the efficacy displayed by carfilzomib in the relapse
setting, several trials tested carfilzomib as part of upfront
therapy for NDMM patients, either with Rd (KRd) or with
alkylating agents, such as melphalan-prednisone (KMP) or
cyclophosphamide-dexamethasone (KCyd).4-7
Carfilzomib is currently approved with the twice-week-
ly schedule at a dose of 27 mg/m2 over a 2-10-minute
(min) infusion period when administered alone or in com-
bination with lenalidomide and dexamethasone, or at a
dose of 56 mg/m2 over a 30-min infusion period when
given in combination with dexamethasone (Kd).
Nonetheless, other doses (up to 70 mg/m2) and schedules
(once weekly) have been shown to be promising.
The current twice-weekly schedule may not be very
convenient for patients (particularly for  elderly patients
with limited access to hospital facilities), affecting their
quality of life and treatment compliance. In order to
improve the convenience of the carfilzomib schedule, pre-
liminary studies tested higher doses of carfilzomib admin-
istered in a once-weekly schedule. The phase Ib/II
CHAMPION-1 study tested different doses of once-week-
ly carfilzomib in RRMM patients to define its maximum
tolerated dose (MTD) combined with dexamethasone.8
The MTD of once-weekly carfilzomib proved to be 70
mg/m2 over a 30-min infusion period, displaying good effi-
cacy and tolerability. Based on these results, a phase III
study (ARROW) was initiated to compare twice-weekly
carfilzomib at the dose of 27 mg/m2 with once-weekly
carfilzomib at the dose of 70 mg/m2.9 Among 578 RRMM
patients, once-weekly carfilzomib improved the overall
response rate (ORR; 62.9% vs. 40.8%) and prolonged
median progression-free survival (PFS) as compared to
twice-weekly carfilzomib (median PFS, 11.2 vs. 7.6
months), with a similar rate of grade 3-4 adverse events
(68% vs. 62%). A major limitation of the ARROW study
was the low dose (27 mg/m2) of carfilzomib in the twice-
weekly arm as compared to the 70 mg/m2 dose adopted in
the once-weekly arm. This low dose was determined
according to the carfilzomib approval at the time of study
design.
We previously published data from two phase I/II (IST-
CAR-561) and  phase II (IST-CAR-506) studies investigat-
ing once-weekly (70 mg/m2) and twice-weekly (36 mg/m2)
carfilzomib combined with cyclophosphamide and dex-
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Table 1. Patients' characteristics.
                                                            All patients                              IST-CAR-561                 IST-CAR-506                                            P
                                                                N=121                                 Once-weekly                 Twice-weekly                                             
                                                                                                                  N=63                            N=58                                                   
Age, median (range)                                     72 (55-86)                                        72 (60-85)                          71 (55-86)                                                      0.67
≥75 years                                                        31 (26%)                                          14 (22%)                            17 (29%)                                                       0.41
Sex, female                                                       68 (56%)                                          37 (59%)                            31 (53%)                                                       0.59
Serum creatinine, mg/dL,                        0.90 (0.46-3.7)                                  0.82 (0.5-3.7)                   1.00 (0.46-2.92)                                                  0.06
median (range)                                                       
ISS
1                                                                        40 (33%)                                          24 (38%)                            16 (28%)                                                       0.46
2                                                                        38 (31%)                                          19 (30%)                            19 (33%)
3                                                                        43 (36%)                                          20 (32%)                            23 (40%)                                                           
FISH
Standard risk                                                  57 (47%)                                          24 (38%)                            33 (57%)                                                        0.4
High risk                                                          37 (31%)                                          19 (30%)                            18 (31%)
Missing                                                            27 (22%)                                          20 (32%)                             7 (12%)                                                            
Frailty Score                                                             
Fit                                                                      67 (55%)                                          37 (59%)                            30 (52%)                                                       0.19
Intermediate fitness                                    40 (33%)                                          22 (35%)                            18 (31%)
Frail                                                                  14 (12%)                                            4 (6%)                              10 (17%)                                                           
LDH, [UI/mol] median (range)                296 (81-768)                                   306 (100-768)                     278 (81-654)                                                    0.35    
Missing                                                            20 (17%)                                            2 (3%)                              18 (31%)                                                           
N: number; IQR: interquartile range; LDH: lactate dehydrogenase; ISS: International Staging System; FISH: fluorescence in situ hybridization.
amethasone (KCyd) as initial treatment for transplant-
ineligible NDMM patients.6,7 In both trials, KCyd was
shown to be a safe and effective option for NDMM
patients. Here we report the results of a pooled analysis of
these two studies.
Methods
Study design and participants
For this analysis, we pooled together data from two phase I/II
(IST-CAR-561; clinicaltrials.gov identifier: 01857115) and phase II
(IST-CAR 506; clinicaltrials.gov identifier: 01346787) studies; these
studies were led by the same co-operative groups. Patients were
recruited from 14 sites across Italy (hospitals, clinics, oncology or
medical centers). Both trials enrolled NDMM patients older than
65 years of age or younger but not eligible for autologous stem-cell
transplantation. Inclusion and exclusion criteria are similar
between the two source studies and have been previously pub-
lished.6,7 Ethics committees or institutional review boards at the
study sites approved both studies, which were carried out in
accordance with the Declaration of Helsinki. All patients provided
written informed consent.
Procedures
In both studies, patients received nine 4-week induction cycles
with carfilzomib, cyclophosphamide (orally, 300 mg on days 1, 8
and 15) and dexamethasone (40 mg on days 1, 8, 15 and 22). In the
IST-CAR 561 study, patients received once-weekly carfilzomib at
the dose of 70 mg/m2 (on days 1, 8 and 15), while in the IST-CAR
506 study patients received twice-weekly carfilzomib at the dose
of 36 mg/m2 (on days 1, 2, 8, 9, 15 and 16). After the induction
phase, patients received maintenance treatment with carfilzomib
as single agent, which was administered at the same dose and
schedule of the induction phase and until progressive disease or
intolerable toxicity. Details of study procedures have been previ-
ously published.6,7 
Outcomes
Focusing on patients who received once- versus twice-weekly
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Figure 1. Analysis profile. N: number; AE: adverse events; PD: pro-
gressive disease; SPM: second primary malignancy.
carfilzomib, the primary goals of this analysis were: (1) to com-
pare PFS, PFS-2 and OS from the date of entry onto the trial in the
intention-to-treat (ITT) population; (2) to compare PFS from start
of maintenance therapy (PFS_m), PFS 2 from start of maintenance
therapy (PFS-2_m)  and overall survival from start of maintenance
therapy (OS_m) in a population who completed the induction
phase and started maintenance treatment. (Note that PFS-2 was
calculated from the date of enrollment to the date of second
relapse/progression or death or the date the patient was last
known to be in remission.) 
Secondary end points were responses, time to response, and
safety of once- versus twice-weekly carfilzomib.
Responses were recorded at the beginning of every cycle,
according to the International Myeloma Working Group (IMWG)
criteria. All adverse events (AE) were assessed during each cycle
and graded according to the National Cancer Institute's Common
Terminology Criteria for Adverse Events (version 4.0).10
Fluorescence in situ hybridization (FISH) was centrally assessed
with a 10% cut-off for numerical aberrations and a 15% cut-off
for IgH translocations; high-risk FISH was defined by the presence
of at least one of the following chromosomal abnormalities:
del(17p), t(4;14) or t(14;16).11 Frailty status was evaluated accord-
ing to the IMWG Frailty Score.12
The intention-to-treat population consisted of all the enrolled
patients and was the basis for the analysis of efficacy end points.
Patients were analyzed according to initial treatment assignment.
The safety population was defined as all the enrolled patients who
received at least one dose of carfilzomib, cyclophosphamide or
dexamethasone, and was the basis for the analysis of the safety
end points.
Statistical analysis
Data from the two studies were pooled together and analyzed.
Comparisons between different patient groups were investigated
using Fisher exact test. Time to response was calculated from the
start of treatment to the date of the first response [complete remis-
sion (CR), partial remission (PR)]. PFS was calculated from the date
of enrollment to the date of progression or death or the date the
patient was last known to be in remission. PFS-2 was calculated
from the date of enrollment to the date of second relapse/progres-
sion or death or the date the patient was last known to be in
remission. OS was calculated from the date of enrollment to the
date of death or the date the patient was last known to be alive.
PFS_m, PFS-2_m and OS_m were calculated from the date of the
start of maintenance therapy. In order to account for potential con-
founders, the comparison once- versus twice-weekly carfilzomib
was adjusted for age, International Staging System (ISS), FISH,
Frailty Score, and, in relation to the maintenance analysis, for
response to induction therapy.
Time-to-event data were analyzed using the Kaplan-Meier
method; survival curves were compared with the log-rank test.
Results are presented as hazard ratios (HRs), 95% confidence
intervals (95% CIs), and two-sided P-values. Data were censored
on September 30th 2015 for the IST-CAR-506 study and on April
30th 2018 for the IST-CAR-561 study. Data were analyzed using
R software (version 3.5.1).
Results
One hundred and twenty-one transplant-ineligible
NDMM patients were analyzed: 63 from the IST-CAR-
Once- vs. Twice-Weekly Carfilzomib in NDMM
haematologica | 2019; 104(8) 1643
Table 2. Grade 3-5 treatment-related adverse events during induction and maintenance therapy.
Grade 3-5 AE                                                                                         IST-CAR-561                                                         IST-CAR-506
                                                                                                             Once-weekly                                                        Twice-weekly
                                                                                                                N=63 (%)                                                              N=56 (%)
                                                                                                                                                    Overall
At least 1 hematologic AE                                                                                            15 (24)                                                                               17 (30)
Anemia                                                                                                                             2 (3)                                                                                   6 (11)
Neutropenia                                                                                                                 13 (21)                                                                               12 (21)
Thrombocytopenia                                                                                                        4 (6)                                                                                    3 (5)
At least 1 non-hematologic AE                                                                                   24 (38)                                                                               23 (41)
Cardiac                                                                                                                             4 (6)                                                                                    5 (9)
- Heart failure                                                                                                             3 (5)                                                                                    2 (4)
-  Myocardial infarction                                                                                                 0                                                                                       1 (2)
- Atrial fibrillation/flutter                                                                                             0                                                                                       2 (4)
-  Sudden death                                                                                                           1 (2)                                                                                       0
Vascular                                                                                                                           5 (8)                                                                                   6 (11)
-  Hypertension                                                                                                             4 (6)                                                                                    2 (4)
Gastrointestinal                                                                                                               3 (5)                                                                                    3 (5)
Infection                                                                                                                          5 (8)                                                                                    3 (5)
Nervous                                                                                                                           2 (3)                                                                                    3 (5)
Respiratory                                                                                                                     4 (6)                                                                                    1 (2)
-  Pulmonary edema                                                                                                   3 (5)                                                                                    1 (2)
Fatigue                                                                                                                                   0                                                                                       3 (5)
Creatinine increase                                                                                                        2 (3)                                                                                       0
At least 1 dose reduction for carfilzomib                                                                18 (29)                                                                               17 (30)
Patients who discontinued carfilzomib due to AE                                                17 (27)                                                                               17 (30)
AE: adverse events.
561 study (once-weekly carfilzomib) and 58 from the 
IST-CAR-506 study (twice-weekly carfilzomib). Patients'
characteristics are listed in Table 1. The median age at
diagnosis in the entire population was 72 years (range, 55-
86 years). Cytogenetic data were available in 94 patients:
37 (31%) had high-risk chromosomal abnormalities by
FISH, including 10% of patients with t(4;14), 3% with
t(14;16), and 18% with del(17p), while 57 patients (47%)
were classified as standard-risk. No significant differences
were observed in the two groups between the percentage
of patients with ISS 3 disease (32% vs. 40%; P=0.45),
high-risk FISH (30% vs. 31%; P=0.40) or Frailty Score (6%
vs. 17%; P=0.09). The median follow up of the entire
cohort was 39 months [interquartile range (IQR): 31-47],
without any difference between the two groups.
Overall, 119 of 121 patients enrolled in the studies start-
ed induction therapy (Figure 1): 63 in the once-weekly
group and 56 in the twice-weekly group. Two patients did
not start therapy in the twice-weekly group: one with-
drew consent and one  was lost to follow up. Ninety
patients entered the maintenance phase: 47 (75%) and 43
(74%) in the once- and twice-weekly groups, respectively
(Figure 1).
In the ITT population, the median PFS from enrollment
was 35.7 months (95%CI: 23.7-NR) in the once-weekly
group and 35.5 months (95%CI: 24.3-NR) in the twice-
weekly group, with, respectively, 47% and 49% of
patients alive and free from progression at three years
(Figure 2A). When adjusting for age, ISS, FISH, and Frailty
Score, no significant differences in the risk of progression
or death were observed between the once-weekly and the
twice-weekly carfilzomib groups (HR: 1.39; P=0.26).
Median PFS-2 was similar in patients receiving once-
weekly (48.6 months; 95%CI: 36.5-NR) and twice-weekly
(48.5 months; 95%CI: 44.1-NR) carfilzomib (HR: 1.25;
P=0.51) (Figure 2B). At three years, median OS was not
reached in either group, with 70% and 72% of patients
alive in the two groups, respectively (Figure 2C). No dif-
ference in the risk of death was observed between the
once-weekly and the twice-weekly carfilzomib groups
when adjusting for age, ISS, FISH and Frailty Score (HR:
1.27; P=0.50). We also assessed PFS and OS according to
cytogenetic risk. No significant difference in 3-year PFS
(52% vs. 43%; HR: 0.76; P=0.38) and 3-year OS (78% vs.
73%; HR: 0.71; P=0.36) was reported between standard-
and high-risk FISH patients, with a greater reduction in the
risk of progression or death in the once-weekly (HR: 1.17;
P=0.72) than in the twice-weekly carfilzomib group (HR:
0.52; P=0.12; interaction P=0.19). 
The median duration of maintenance was 17 months
(IQR: 4-28) in the once-weekly and 20 months (IQR 7-32)
in the twice-weekly group (P=0.17). At three years, PFS_m
S. Bringhen et al.
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Figure 2. Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma. (A) Intention-to-treat progression-free survival (ITT PFS).
(B) Intention-to-treat progression-free survival 2 (ITT PFS-2). (C) Intention-to-treat overall survival (ITT OS). (Note that PFS-2 was calculated from the date of enrollment
to the date of second relapse/progression or death or the date the patient was last known to be in remission.) 
B
C
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was 47% (95%CI: 33%-68%) and 51% (95%CI: 38%-
70%) in the once-weekly group and in the twice-weekly
group, respectively (Figure 3A), with no significant differ-
ence in the risk of progression (HR: 1.04; P=0.92) within
the two groups when adjusting for age, ISS, FISH, Frailty
Score and response to induction. No differences in 3-year
PFS-2_m (65% vs. 74%; HR: 0.85; P=0.74) and OS_m
(72% vs. 73%; HR: 0.82; P=0.71) were observed between
the two groups (Figure 3B and C).
Overall, the proportion of patients achieving a PR or
better was 92% in the once-weekly versus 90% in the
twice-weekly group (P=0.76), including 22% and 29% of
patients obtaining a CR or better (P=0.41). Responses
were rapid: median time to PR or better was 1.9 months
in the once-weekly group and 1.2 months in the twice-
weekly group.
Carfilzomib dose reduction was necessary in 18 (29%)
patients receiving the once-weekly schedule and in 17
(30%) patients receiving the twice-weekly schedule. The
median relative dose intensity of carfilzomib [once week-
ly 97.6% (IQR 88.3-100%); twice weekly 97.2% (IQR
90.4-100%)] was similar in the two groups (P=0.75).
Dexamethasone dose reduction was necessary in 13
(21%) patients receiving the once-weekly schedule and in
18 (32%) patients receiving the twice-weekly schedule.
The median relative dose intensity of dexamethasone
[once weekly 100% (IQR 82.6-100%); twice weekly
100% (IQR 88.5-100%)] was similar in the two groups
(P=0.85). Cyclophosphamide dose reduction was neces-
sary in 7 (11%) patients receiving the once-weekly sched-
ule and in 15 (27%) patients receiving the twice-weekly
schedule. Nevertheless, the median relative dose intensity
of cyclophosphamide [once weekly 96.85% (IQR 90.8-
100%); twice weekly 96.75% (IQR 88.6-100%)] was sim-
ilar in the two groups (P=0.97). The most common AE
leading to carfilzomib dose reduction were acute kidney
injury (1 patient in the once-weekly group and 2 patients
in the twice-weekly group), infections (2 patients in each
group), and hypertension (4 patients in the once-weekly
group and none in the twice-weekly group). Treatment-
related AE leading to the discontinuation of carfilzomib
occurred in 17 (27%) patients in the once-weekly group
and 17 (30%) patients in the twice-weekly group. The
most common AE leading to carfilzomib discontinuation
were cardiac injury (6 patients in the once-weekly group
and 6 patients in the twice-weekly group), infections (3
patients in the once-weekly group and 3 patients in the
twice-weekly group), and thromboembolism (2 patients
in the once-weekly group and 1 in the twice-weekly
group). Cardiac events leading to drug discontinuation
during induction (3 and 2) and maintenance (3 and 4)
occurred at similar rates in patients receiving once- versus
Once- vs. Twice-Weekly Carfilzomib in NDMM
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Figure 3. Analysis from start of maintenance therapy. (A) Progression-free survival from start of maintenance therapy (PFS_m). (B) Progression-free survival 2 from
start of maintenance therapy (PFS-2_m). (C)  Overall survival from start of maintenance therapy (OS_m). (Note that PFS-2 was calculated from the date of enrollment
to the date of second relapse/progression or death or the date the patient was last known to be in remission.) 
A B
C
twice-weekly carfilzomib, respectively. Similarly, the rates
of infections leading to drug discontinuation were similar
during induction (2 and 3) and maintenance (1 and 0)
between the once- versus twice-weekly groups.
Overall, the incidence of treatment-related grade 3-5 AE
was similar in the once-weekly and the twice-weekly
carfilzomib groups, both in terms of hematologic (24% vs.
30%; P=0.82) and non-hematologic (38% vs. 41%; 
P= 0.83) AE. The most frequent non-hematologic grade ≥3
AE were infections [5 (8%) in the once-weekly group vs.
3 (5%) in the twice-weekly group], respiratory [4 (6%) vs.
1 (2%)], cardiac [4 (6%) vs. 5 (9%)] and hypertension [4
(6%) vs. 2 (4%)]. The incidence of treatment-related grade
3-5 AE during carfilzomib maintenance was low, with
comparable rates of hematologic (0% vs. 5%) and non-
hematologic (21% vs. 23%) AE in the once-weekly and
the twice-weekly groups. The most frequent ≥3 AE was
hypertension [4 (9%) vs. none]. All AE are reported in
Table 2.
Discussion
In this pooled analysis of two phase I/II studies compar-
ing two alternative schedules of carfilzomib, transplant-
ineligible NDMM patients who received once-weekly
carfilzomib at the dose of 70 mg/m2 showed similar
response rates as compared to patients treated with twice-
weekly carfilzomib at the dose of 36 mg/m2. Moreover,
the analysis did not report differences in terms of PFS, PFS-
2, and OS. Administering high-dose carfilzomib (70
mg/m2) in a once-weekly schedule did not impair the safe-
ty profile of the KCyd combination in comparison with a
lower (36 mg/m2) twice-weekly schedule.
To date, two doses of twice-weekly carfilzomib, 27
mg/m2 and 56 mg/m2, have been approved for the treat-
ment of RRMM patients, based on the results of the phase
III ASPIRE and ENDEAVOR trials. In the ASPIRE study,
carfilzomib was tested at the dose of 27 mg/m2.13
However, a higher dose of carfilzomib (36 mg/m2) had
been investigated in combination with lenalidomide and
dexamethasone, and was shown to be safe and effective
for NDMM patients.4,14-16 In the ENDEAVOR trial, which
compared Kd versus bortezomib-dexamethasone (Vd),
carfilzomib was administered at the dose of 56 mg/m2.17,18 
Despite the great results yielded by the introduction of
carfilzomib, treatment compliance and quality of life of
young active patients, as well as those of elderly patients
with reduced mobility, are compromised by the need for
frequent visits to the outpatient clinic for carfilzomib dos-
ing. From this point of view, a shift from the current
twice-weekly to a once-weekly dosing schedule would
decrease by 50% patient visits to health care facilities,
with a subsequent improvement in quality of life and a
reduction in drug and health care costs. For these purpos-
es, higher doses of carfilzomib, administered once-week-
ly, were tested in the relapse setting in a phase Ib/II study
and in a subsequent phase III study.6-9 Once-weekly carfil-
zomib yielded a higher ORR as compared to twice-week-
ly carfilzomib, resulting in prolonged median PFS (11.2 vs.
7.6 months) without significantly increasing the rate of AE
or the risk of treatment discontinuation due to AE.
However, the major limitation of the ARROW study was
the low dose adopted for the twice-weekly arm, which
was chosen by the investigators because it was the
approved dose at the time of trial design. Indeed, higher
doses of carfilzomib (up to 36 mg/m2 when given in com-
bination and 70 mg/m2 alone) have been safely delivered
both in upfront and relapse settings.5,8,14-20
To our knowledge, this is the first analysis to compare
two different schedules and doses of carfilzomib (70
mg/m2 once-weekly vs. 36 mg/m2 twice-weekly) as induc-
tion and maintenance therapies for elderly, transplant-inel-
igible NDMM patients.
In the ITT analysis, we observed no significant differ-
ences in 3-year PFS (47% vs. 49%), PFS-2 (62% vs. 70%)
and OS (70% vs. 72%) in patients receiving once- versus
twice-weekly carfilzomib. The risks of dose reduction or
treatment discontinuation were equal between the two
groups. Of note, delivering 70 mg/m2 of carfilzomib in a
single dose did not increase the risk of grade 3-5 hemato-
logic (24% vs. 30%; P=0.82) and non-hematologic (38%
vs. 41%; P=0.83) AE, as compared to a twice-weekly
administration of 36 mg/m2 of carfilzomib. Importantly,
no new cardiovascular safety risks were identified with
once-weekly carfilzomib treatment at the 70 mg/m2 dose.
The aim of continuous treatment is to prolong PFS and
OS among NDMM patients without negatively affecting
their quality of life. For this purpose, we compared once-
versus twice-weekly maintenance with carfilzomib.
Among patients who received carfilzomib maintenance,
we did not observe any significant differences in terms of
3-year PFS_m (47% vs. 51%), PFS-2_m (65% vs. 74%), and
OS_m (72% vs. 73%) between the once-weekly and
twice-weekly schedules. Continuous treatment with sin-
gle-agent carfilzomib was well tolerated and grade 3-5 AE
were infrequent in both groups, although patients in the
once-weekly arm were at higher risk of developing grade
3-5 hypertension (9% vs. 0%) as compared to patients in
the twice-weekly group.
As previously reported, carfilzomib is able to at least
partially abrogate the unfavorable prognostic significance
of high-risk FISH cytogenetic abnormalities.21 In this trial,
we observed no difference between standard and high-
risk FISH patients in terms of 3-year PFS (52% vs. 43%)
and OS (78% vs. 73%), with a greater reduction in the risk
of progression or death for high-risk FISH patients (as
compared to standard-risk FISH patients) in the once-
weekly (HR: 1.17) than in the twice-weekly (HR: 0.52)
carfilzomib schedule. These results compared favorably
with those observed in the ARROW trial.9 However, due
to the high frequency of patients with unknown cytoge-
netic risk and the small number of patients, these results
should be interpreted with caution and this evidence must
be confirmed by further studies.
The major limitation of our analysis was the non-ran-
domized design of the two phase I/II studies. Indeed, the
study populations were slightly different (e.g. frailty sta-
tus, FISH data availability), but the most important inclu-
sion and exclusion criteria, as well as the treatment
schema, were identical. Furthermore, the reproducibility
of the results in the community setting was limited both
by the lower percentage of older patients (≥75 years) as
compared to other studies (such as the FIRST and the
ALCYONE), and by the fact that patients included in this
analysis were treated in the context of clinical trials in a
limited number of selected, experienced centers. With this
limitation, our results should be interpreted with caution,
even though they should be considered as the basis of
future randomized trials.
S. Bringhen et al.
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In conclusion, a once-weekly 70 mg/m2 infusion of
carfilzomib was shown to be as safe and effective as a
twice weekly 36 mg/m2 infusion for the initial treatment
of elderly transplant-ineligible NDMM patients, both as
induction therapy in combination with cyclophos-
phamide and dexamethasone and as single-agent mainte-
nance. This analysis supports the use of high-dose once-
weekly carfilzomib and provides the rationale for the
investigation of once- versus twice-weekly carfilzomib as
initial treatment for MM patients.
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